SCHEMBL7960703

SCHEMBL7960703

OC1(CBr)CCCc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
SIGMAR1 Q99720 8/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
DRD2 P14416 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTR2B P41595 1/20 0.41
MTOR P42345 1/20 0.41
AKR1B1 P15121 1/20 0.41
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19130231 0.82 KDM1A (0.47) KDM1AMEN1KMT2ASIGMAR1TP53
SCHEMBL6691850 0.82 KDM1A (0.47) KDM1AMEN1KMT2ASIGMAR1TP53
SCHEMBL1333907 0.82 KDM1A (0.47) KDM1AMEN1KMT2ASIGMAR1TP53
SCHEMBL11079679 0.79 KDM1A (0.45) KDM1AMEN1KMT2ASIGMAR1TP53
SCHEMBL4420303 0.79 SIGMAR1 (0.49) KDM1AMEN1KMT2ASIGMAR1TP53
SCHEMBL15891588 0.78 CASP6 (0.45) KDM1AMEN1KMT2ASIGMAR1TP53
SCHEMBL19124508 0.77 SIGMAR1 (0.47) KDM1AMEN1KMT2ASIGMAR1TSHR
SCHEMBL19130781 0.77 SIGMAR1 (0.47) KDM1AMEN1KMT2ASIGMAR1TSHR
SCHEMBL6917152 0.76 KDM1A (0.47) KDM1AMEN1KMT2ASIGMAR1TP53
SCHEMBL31629514 0.75 KDM1A (0.50) KDM1AMEN1KMT2ASIGMAR1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
WO-2010021680-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218192-A1 Inhibitors Of Beta-Secretase BACE1, BACE2, APP KDM1A 2831/4885MEN1 813/4885KMT2A 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.